Amplitude Healthcare Acquisition filed an S-4 registration statement outling terms of its proposed merger with Jasper Therapeutics.
The business combination would give Jasper a market capitalizzation of approximately $490 million.
Pending shareholder approval, the deal is expected to close in the third quarter when Jasper Therapeutics common stock would list on the Nasdaq under JSPR.
The deal will be funded through a combination of approximately $100 million cash in trust by Amplitude (less any redemptions) and a $100 million concurrent PIPE of common stock issued at $10 per share. As part of the transaction, Jasper Therapeutics’ existing equity holders will roll 100 percent of their equity into the combined company.
A vote date for Amplitude shareholders is not listed in the preliminary proxy. Read more.
